3 quick facts on Integra LifeSciences’ financial outlook

Integra LifeSciences Holdings shares received a crowd sourced rating of four on a scale of one to five, on which five is a considered a “strong buy,” according to Uptick Analyst.

Advertisement

Here are three quick facts:

 

1. Zacks’ analysts estimate the company shares will hit between $55 and $80 in the next year.

 

2. Zacks’ analysts gave Integra LifeSciences an average broker rating of 1.85.

 

3. Integra LifeSciences Holdings’ headquarters are in Plainsboro, N.J.

 

More articles on devices:
EOS imaging partners with Spinologics — 5 highlights
Technavio: Global reverse shoulder arthroplasty market to grow — 5 takeaways
National Science Foundation awards SBIR grant to OsteoVantage — 4 notes

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.